Cargando…
Targeting the right regulatory T-cell population for tumor immunotherapy
Regulatory T cells (Tregs) that suppress tumor-specific T cell-mediated immune responses are the subject of an intense wave of investigation. We recently reported that a subset of Tregs, namely effector/memory CD25(low) cells, are responsible for suppressing high avidity tumor-specific T cells in mo...
Autores principales: | Weiss, Vivian L., Lee, Timothy H., Jaffee, Elizabeth M., Armstrong, Todd D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494642/ https://www.ncbi.nlm.nih.gov/pubmed/23170276 http://dx.doi.org/10.4161/onci.20664 |
Ejemplares similares
-
IL-21 in cancer immunotherapy: At the right place at the right time
por: Santegoets, Saskia JAM, et al.
Publicado: (2013) -
Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy
por: Shen, Li, et al.
Publicado: (2012) -
A new strategy to target regulatory T cells in solid tumors
por: Thomas-Schoemann, Audrey, et al.
Publicado: (2013) -
Discovering cancer immunotherapy targets in vivo
por: Zhou, Penghui, et al.
Publicado: (2014) -
Cancer cell associated glycans as targets for immunotherapy
por: Vankemmelbeke, Mireille, et al.
Publicado: (2015)